The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Clinical & Manufacturing

Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria
Clinical & Manufacturing

Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria

SEP 20, 2021
Fecal transplant plus fibre improves insulin sensitivity in severely obese
Clinical & Manufacturing

Fecal transplant plus fibre improves insulin sensitivity in severely obese

JUL 6, 2021
Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology
Clinical & Manufacturing

Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

JUN 23, 2021
New Double-Blind Randomized Placebo-Controlled Trial Confirms Hafnia alvei HA4597® helps improve weight loss in overweight adults
Clinical & Manufacturing

New Double-Blind Randomized Placebo-Controlled Trial Confirms Hafnia alvei HA4597® helps improve weight loss in overweight adults

JUN 15, 2021
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
Clinical & Manufacturing

4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update

JUN 7, 2021
Ferring and Rebiotix Present Landmark Phase 3 Data
Clinical & Manufacturing

Ferring and Rebiotix Present Landmark Phase 3 Data

MAY 24, 2021
Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132
Clinical & Manufacturing

Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132

FEB 3, 2021
Why microbiota samples should be collected in all clinical trials?
Clinical & Manufacturing

Why microbiota samples should be collected in all clinical trials?

JAN 26, 2021
Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections
Clinical & Manufacturing

Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections

JAN 20, 2021
Leading immune-focused microbiome drug company taps Biose Industrie for manufacturing expertise
Clinical & Manufacturing

Leading immune-focused microbiome drug company taps Biose Industrie for manufacturing expertise

NOV 27, 2020
The Microbiome Drug Landscape report: Promising clinical performance and signs of a maturing industry
Clinical & Manufacturing

The Microbiome Drug Landscape report: Promising clinical performance and signs of a maturing industry

OCT 26, 2020